Loading organizations...
NeuroDerm has raised $3.0M across 1 funding round.
Key people at NeuroDerm.
NeuroDerm has raised $3.0M in total across 1 funding round.
NeuroDerm develops drug-device combination solutions for central nervous system disorders. It integrates proprietary pharmaceutical formulations with advanced delivery systems and digital health technologies. This approach creates comprehensive treatments, enhancing drug delivery efficacy and improving patient outcomes beyond current therapeutic limitations.
Founded in 2003 by Eli Heldman as an incubator company, NeuroDerm addressed critical unmet needs in neurological care. Dr. Oded Lieberman assumed the role of CEO in 2007. The company’s initial insight focused on achieving continuous levodopa delivery, a significant objective in Parkinson’s disease treatment.
NeuroDerm primarily serves patients affected by central nervous system disorders, notably Parkinson’s disease. Its vision is to improve their quality of life by pioneering and delivering patient-centric therapies. The company strives to transform neurological care through integrating pharmaceutical innovation and medical technology.
NeuroDerm has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in July 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2007 | $3M Series A | — | — | Announced |
NeuroDerm is a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders, developing proprietary reformulations of existing drugs for continuous subcutaneous or transdermal administration to enhance clinical efficacy.[1][2][3] Its lead product candidates, such as ND0612L for Parkinson's disease, address limitations of oral therapies like levodopa/carbidopa (LD/CD) by enabling steady delivery, reducing fluctuations that cause "off" time and dyskinesia.[3] The company serves patients with CNS conditions including Parkinson's, Alzheimer's, schizophrenia, and ADD/ADHD, solving key problems of poor bioavailability, inconsistent dosing, and invasive delivery methods through liquid formulations and patches.[3][4] Now part of the Mitsubishi Tanabe Pharma Group, NeuroDerm integrates pharmaceutical formulations, advanced delivery systems, and digital health solutions, showing growth via Phase II trials and acquisition.[2][6]
NeuroDerm, founded as a clinical-stage pharmaceutical company with a limited operating history, emerged from expertise in reformulating approved drugs for CNS disorders, particularly focusing on liquid versions of LD/CD for Parkinson's—the first of their kind for continuous subcutaneous use.[3] Key early milestones include completing a Phase II study for ND0612L and advancing ND0801, a nicotine-based transdermal patch for cognition disorders in ADD/ADHD, Alzheimer's, schizophrenia, and Parkinson's.[3] The company gained significant traction through acquisition by Mitsubishi Tanabe Pharma America, integrating it into a larger group while maintaining its agile, entrepreneurial R&D focus on patient-centric innovations.[2][6]
NeuroDerm rides the wave of precision drug delivery in CNS therapeutics, where market forces like aging populations and rising neurodegenerative disease prevalence (e.g., Parkinson's affecting millions) demand better alternatives to oral therapies' inconsistencies.[3] Timing aligns with advances in subcutaneous infusion tech and digital health integration, reducing reliance on surgery-heavy options like deep brain stimulation.[1][4] It influences the ecosystem by pioneering reformulation strategies that lower development risks via 505(b)(2) pathways, inspiring similar biopharma-medtech hybrids and accelerating patient access through partnerships like Mitsubishi Tanabe.[2][3][6]
NeuroDerm's trajectory points to Phase III trials for ND0612L and potential launches under Mitsubishi Tanabe, capitalizing on subcutaneous delivery's edge in Parkinson's amid growing demand for fluctuation-free therapies.[2][3] Trends like AI-driven formulations and wearable medtech will shape its path, potentially expanding cognition pipeline amid CNS market growth. Its influence may evolve from innovator to scaled platform within a pharma giant, redefining reformulation for chronic diseases—echoing its core mission to transform existing drugs into life-changing continuous therapies.[1][7]
Key people at NeuroDerm.
NeuroDerm has raised $3.0M in total across 1 funding round.
